Fig 1: DLX2 expression leads to reduced Triple T complex component levels. (A) DLX2 induction led to reduced TTI1 protein level in E7 BJ and IMR90 cells. (B) DLX2 induction led to reduced TEL2 protein levels in IMR90 cells. (C) DLX2 induction did not alter the mRNA level of TTI1, TTI2, and TEL2. (D) Leupeptin treatment restored DLX2-induced ATM protein reduction. E7 BJ cells with inducible DLX2 were induced with 1 µg/mL doxycycline for 5 d and then treated with DMSO or 100 µM leupeptin 24 hr prior to harvesting. (E) Statistics of DLX2–p53 mutual exclusivity. The P-value was calculated by Fisher's exact test. (F) Visual overview of patients with DLX2 overexpression and p53 alteration. Data from all 971 patients are plotted horizontally on the X-axis, with each bar representing five patients. (Top row) p53 alteration status. (Blue) Cases with p53 alteration; (gray) normal p53. (Bottom row) DLX2 overexpression status. (Red) Cases with DLX2 overexpression; (gray) normal DLX2 expression levels. Data were acquired from the cBioPortal Web tool (http://www.cbioportal.org).